125
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Lipid peroxidation products as predictors of oxidant-mediated disease in preterm infants

, , , , &
Pages 4878-4883 | Received 11 Aug 2020, Accepted 23 Dec 2020, Published online: 04 Jan 2021
 

Abstract

Background

Preterm infants are susceptible to “oxygen radical diseases” (ORD). 8-isoprostane (8-IP) is a bioactive eicosanoid generated by reactive oxygen species-catalyzed peroxidation of arachidonic acid. Malondialdehyde (MDA) is generated by the decomposition of oxidant-induced lipid hydroperoxides. We hypothesize that the development of ORD is associated with elevated plasma 8-IP on day 0–1, and increasing urine levels of MDA in the first month.

Methods

Preterm (<32 weeks, n = 39) and term (n = 39) infants were recruited at birth. Plasma 8-IP was quantified by ELISA on day 0–1, and urine MDA by colorimetric assay of thiobarbituric acid reactive substances (TBARS) on days 0–1, 7, 14, 21, and 28. ORD was defined as retinopathy of prematurity ≥ stage 1, pneumatosis, or oxygen requirement at 36 weeks corrected gestational age.

Results

Plasma 8-IP was higher on day 0–1 in preterm infants who developed ORD compared to term infants. Urine TBARS levels increased in preterm infants from day 0–1 to day 28 but were not different in infants with or without ORD. Preterm infants who developed ORD demonstrated a significant rise in urine TBARS levels from day 1 to 14.

Conclusions

Elevated plasma 8-IP on day 1 is associated with ORD in preterm infants. If validated as a biomarker for ORD, it may be useful in directing antioxidant therapies to the most susceptible infants. Urine TBARS during the first month are not significantly different in term infants, preterm infants with ORD, and preterm infants without ORD, but rapid rise of TBARS in the first 2 weeks may be associated with ORD.

Disclosure statement

All authors have indicated they have no potential conflicts of interest to disclose. No honorarium, grant, or other form of payment was given to anyone to produce the manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.